Human medicines European public assessment report (EPAR): Tobi Podhaler, tobramycin, Date of authorisation: 20/07/2011, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR): Camcevi, leuprorelin, Date of authorisation: 24/05/2022, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Imuldosa, ustekinumab, Date of authorisation: 12/12/2024, Revision: 6, Status: Authorised

PSUSA/00002702/202509

PSUSA/00002904/202509

PSUSA/00010582/202509

Human medicines European public assessment report (EPAR): Omlyclo, omalizumab, Date of authorisation: 16/05/2024, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Exdensur, depemokimab, Date of authorisation: 12/02/2026, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Qalsody, tofersen, Date of authorisation: 29/05/2024, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Amglidia, glibenclamide, Date of authorisation: 24/05/2018, Revision: 9, Status: Authorised